Trial · NCT07901621
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Peak Oxygen Uptake (VO2peak) | Week 0 (baseline) and week 13 (post-intervention) | Highest 30-second average oxygen uptake during a maximal treadmill test (Bruce protocol) with breath-by-breath gas analysis (Cortex Metalyzer 3B), in mL/kg/min. First outcome in the pre-specified fixed-sequence testing hierarchy. |
| Primary | Resting Systolic Blood Pressure | Week 0 (baseline) and week 13 (post-intervention) | Automatic upper-arm monitor (OMRON HBP-1120-BR); three readings at 1-minute intervals after 5 minutes of seated rest; mean of the last two readings, in mmHg. Second in the testing hierarchy. |
| Primary | Resting Diastolic Blood Pressure | Week 0 (baseline) and week 13 (post-intervention) | Same procedure as systolic blood pressure, in mmHg. Third, in the testing hierarchy. |
| Primary | Physical Health-Related Quality of Life (KDQOL-SF v1.3 Physical Component Summary) | Week 0 (baseline) and week 13 (post-intervention) | Physical Component Summary (PCS) of the SF-36 core of the Kidney Disease Quality of Life Short Form (KDQOL-SF v1.3, Brazilian version), reported as a single summary score on a norm-based T-score scale (general population mean 50, SD 10); higher scores indicate better physical health. Fourth in the testing hierarchy. |
| Primary | Estimated Glomerular Filtration Rate (eGFR) | Week 0 (baseline) and week 13 (post-intervention) | eGFR by the race-free CKD-EPI 2021 creatinine-cystatin C equation, from fasting blood samples, in mL/min/1.73 m2. Fifth in the testing hierarchy. |
| Secondary | Balance (Mini-BESTest) | Week 0 (baseline) and week 13 (post-intervention) | Mini-Balance Evaluation Systems Test total score (0-28; higher = better balance), Brazilian Portuguese version. |
| Secondary | Falls | During the 12-week intervention | Number of participants with at least one fall and fall incidence per group, recorded prospectively with monthly falls calendars (fall defined per ProFaNE consensus). |
| Secondary | Agility and Dynamic Balance (8-Foot Up and Go Test) | Week 0 (baseline) and week 13 (post-intervention) | 8-Foot Up and Go test; best time of two valid attempts, in seconds. |
| Secondary | Handgrip Strength | Week 0 (baseline) and week 13 (post-intervention) | Jamar dynamometer, dominant hand, best of three attempts, in kgf. |
| Secondary | Lower-Limb Muscle Strength (30-Second Chair Stand Test) | Week 0 (baseline) and week 13 (post-intervention) | 30-second chair stand test, number of repetitions. |
| Secondary | Mental Health-Related Quality of Life (KDQOL-SF v1.3 Mental Component Summary) | Week 0 (baseline) and week 13 (post-intervention) | Mental Component Summary (MCS) of the SF-36 core of the KDQOL-SF v1.3, reported as a single summary score on a norm-based T-score scale (general population mean 50, SD 10); higher scores indicate better mental health. |
| Secondary | Other KDQOL-SF v1.3 Dimensions | Week 0 (baseline) and week 13 (post-intervention) | Scores (0-100) of the remaining generic and kidney disease-specific dimensions; higher scores indicate better quality of life. |
| Secondary | Uremic Toxins and Kidney Markers | Week 0 (baseline) and week 13 (post-intervention) | Serum urea, creatinine, and cystatin C; urinary albumin and protein (first-morning urine). |
| Secondary | Fasting Plasma Glucose | Week 0 (baseline) and week 13 (post-intervention) | Fasting plasma glucose, in mg/dL. |
| Secondary | Glycated Hemoglobin (HbA1c) | Week 0 (baseline) and week 13 (post-intervention) | Glycated hemoglobin (HbA1c), in %. |
| Secondary | Lipid Profile | Week 0 (baseline) and week 13 (post-intervention) | Total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides (mg/dL). |
| Secondary | Apolipoproteins | Week 0 (baseline) and week 13 (post-intervention) | Apolipoprotein A-I and apolipoprotein B, as cardiovascular risk markers. |
| Secondary | Inflammatory Markers | Week 0 (baseline) and week 13 (post-intervention) | Interleukin-6, interleukin-10, tumor necrosis factor-alpha, and high-sensitivity C-reactive protein. |
| Secondary | Vitamin D Status | Week 0 (baseline) and week 13 (post-intervention) | Serum 25-hydroxyvitamin D. |
| Secondary | Lean Mass | Week 0 (baseline) and week 13 (post-intervention) | Whole-body lean mass assessed by dual-energy X-ray absorptiometry (DXA), in kg.Lean mass, fat mass, and body fat percentage (whole-body DXA). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07901621/registered